Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels

Journal of Infectious Diseases

Volumn 209, Issue 12, 2014, Pages 1907-1915

  Jouvin Marche, Evelyne ^a,b   Jílková, Zuzana Macek ^a,b   Thelu, Marie Ange ^a,b,c   Marche, Helene ^a,b   Fugier, Emilie ^a,b   Van Campenhout, Nicolas ^a,b   Hoang, Xuan Su ^a,b   Marlu, Alice ^d   Sturm, Nathalie ^a,b,c   Callanan, Mary ^a,b   Leroy, Vincent ^a,b,c   Zarski, Jean Pierre ^a,b,c   Marche, Patrice N ^a,b,c  

^a INSTITUT ALBERT BONNIOT   (France)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d NONE

Author keywords

interferon lambda; ISG; natural killer cells. T lymphocytes

Indexed keywords

ALANINE AMINOTRANSFERASE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PEGINTERFERON ALPHA; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DEGRANULATION; DISEASE ASSOCIATION; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IFNL4 GENE; LYMPHOCYTE; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRAL CLEARANCE; VIRUS CARRIER; VIRUS LOAD;

INTERFERON LAMBDA; ISG; NATURAL KILLER CELLS. T LYMPHOCYTES;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CELL DEGRANULATION; FATTY LIVER; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LIVER; LYMPHOCYTES; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATURAL KILLER T-CELLS; POLYMORPHISM, GENETIC; RIBAVIRIN; RNA, VIRAL; VIRAL LOAD;

EID: 84901778502     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu016     Document Type: Article

References (38)

1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36:S21-9. (Pubitemid 35253460)
2. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13:34-41.
3. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005; 9:383-98. (Pubitemid 40968202)
4. Shoukry NH, Pelletier S, Chang KM. A view to natural killer cells in hepatitis C. Gastroenterology 2011; 141:1144-8.
5. Howell J, Visvanathan K. The role of natural killer cells in hepatitis C infection. Antivir Ther 2013; 18:853-65.
6. Ahlenstiel G. The natural killer cell response to HCV infection. Immune Netw 2013; 13:168-176.
7. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
8. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-4.
9. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-9.
10. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
11. Prokunina-Olsson L, Muchmore B, TangW, et al. Avariant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 2013; 45:164-71.
12. Helbig KJ, Lau DT, Semendric L, et al. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. Hepatology 2005; 42:702-10. (Pubitemid 41233665)
13. SmithMW, Yue ZN, Korth MJ, et al. Hepatitis C virus and liver disease: global transcriptional profiling and identification of potential markers. Hepatology 2003; 38:1458-67. (Pubitemid 37466972)
14. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-9. (Pubitemid 351754525)
15. Abe H, Hayes CN, Ochi H, et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011; 83:1597-607.
16. Asahina Y, Tsuchiya K, Muraoka M, et al. Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. Hepatology 2012; 55:20-9.
17. Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139:499-509.
18. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119:1745-54.
19. Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52:1888-96.
20. Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011; 53:810-20.
21. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 2012; 61:1226-34.
22. Sturm N, Thelu MA, Camous X, et al. Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. J Hepatol 2010; 53:25-35.
23. Mondelli MU, Varchetta S, Oliviero B. Natural killer cells in viral hepatitis: facts and controversies. Eur J Clin Invest 2010; 40:851-63.
24. Leroy V, Vigan I, Mosnier JF, et al. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology 2003; 38:829-41. (Pubitemid 37221666)
25. Pernollet M, Jouvin-Marche E, Leroy V, et al. Simultaneous evaluation of lymphocyte subpopulations in the liver and in peripheral blood mononuclear cells of HCV-infected patients: relationship with histological lesions. Clin Exp Immunol 2002; 130:518-25. (Pubitemid 35418337)
26. Ahlenstiel G, Edlich B, Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011; 141:1231-9, 1239 e1-2.
27. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281:65-78. (Pubitemid 37324571)
28. Bochud PY, Bibert S, Negro F, et al. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol 2011; 55:980-8.
29. Oliviero B, Varchetta S, Paudice E, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology 2009; 137:1151-60, 1160 e1-7.
30. Rehermann B, Naoumov NV. Immunological techniques in viral hepatitis. J Hepatol 2007; 46:508-20. (Pubitemid 46185711)
31. Urban T, Charlton MR, Goldstein DB. Introduction to the genetics and biology of interleukin-28B. Hepatology 2012; 56:361-6.
32. Abel M, Sene D, Pol S, et al. Intrahepatic virus-specific IL-10-producing CD8T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology 2006; 44:1607-16. (Pubitemid 44953666)
33. Thimme R, Opitz OG. Interleukin-10 and viral clearance: translation to viral hepatitis. Gastroenterology 2007; 132:2611-3. (Pubitemid 46890883)
34. Wedemeyer H, He XS, Nascimbeni M, et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 2002; 169:3447-58. (Pubitemid 35013196)
35. Marabita F, Aghemo A, De Nicola S, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology 2011; 54:1127-34.
36. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120-9 e18.
37. Langhans B, Nischalke HD, Arndt S, et al. Ribavirin exerts differential effects on functions of Cd4+ Th1, Th2, and regulatory T cell clones in hepatitis C. PLoS One 2012; 7:e42094.
38. Deleersnyder V, Pillez A, Wychowski C, et al. Formation of native hepatitis C virus glycoprotein complexes. J Virol 1997; 71:697-704. (Pubitemid 26412343)